Mads Bodenhoff, Senior Vice President and Principal Accounting Officer of Ascendis Pharma A/S (NASDAQ:ASND), filed a Form 4 on September 10, 2026, reporting transactions in ordinary shares and warrants dated September 8, 2026.

Key Highlights

  • Warrant exercise: Bodenhoff exercised 3,000 warrants with an exercise price of $110 per share on September 8, 2026, acquiring 3,000 ordinary shares.
  • Open-market sale: All 3,000 acquired ordinary shares were sold on September 8, 2026, at a price of $270.19 per share.
  • Resulting share ownership: Following the transactions, Bodenhoff directly held 0 ordinary shares, according to the filing.
  • Remaining warrants: Bodenhoff retained 687 warrants directly following the reported transactions, with an expiration date of October 11, 2032.
  • Vesting schedule: The warrants vested 25% on October 11, 2023, and thereafter in 36 equal monthly installments, according to the filing.
  • Filing signatory: The form was signed by Michael Wolff Jensen as attorney-in-fact for Mads Bodenhoff on September 10, 2026.

Bodenhoff's Warrant Exercise and Share Sale at Ascendis Pharma

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Mads Bodenhoff, identified as SVP and Principal Accounting Officer of Ascendis Pharma A/S, reported two transactions on September 8, 2026. The first was the exercise of 3,000 warrants (transaction code M) at a conversion price of $110 per share, resulting in the acquisition of 3,000 ordinary shares. The filing lists the price of the derivative security at $0 in connection with the exercise.

On the same date, Bodenhoff disposed of all 3,000 ordinary shares (transaction code S) at a price of $270.19 per share, leaving him with a direct beneficial ownership of 0 ordinary shares following the reported transactions. The filing records both transactions as direct ownership.

In Table II, the filing discloses that 687 warrants remain directly held by Bodenhoff after the 3,000 warrants were exercised. These warrants carry an exercise price of $110 and an expiration date of October 11, 2032. The filing's explanation of responses states that the warrants "vested 25% on October 11, 2023 and thereafter in 36 equal monthly installments." The issuer is identified as Ascendis Pharma A/S, traded on NASDAQ under the symbol ASND.

What Was Disclosed

The filing reports that Mads Bodenhoff exercised 3,000 warrants at $110 per share and sold all resulting ordinary shares at $270.19 per share on September 8, 2026, leaving him with 0 ordinary shares and 687 remaining warrants directly held.